<\/p>\n
Selgin<\/strong> er en oral selegiline<\/strong> (5 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> brukes til \u00e5 behandle Parkinsons sykdom<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Selegiline is metabolised to L-amphetamine and L-methamphetamine<\/strong>, which can contribute to insomnia — take morning doses only. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Viktig:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotoninsyndrom<\/em>.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Selgin is an oral tablet containing selegiline 5 mg<\/strong>. selegiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Eldepryl \/ Jumex<\/strong>. Selgin is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Selegiline was the first MAO-B inhibitor used in Parkinson disease, in clinical use since the 1980s. It can be used as monotherapy<\/em> in early Parkinson disease (modest symptomatic benefit, may delay the need for levodopa by months) or as tilleggsbehandling<\/em> to levodopa to reduce “wearing-off” between doses. Its distinctive feature among MAO-B inhibitors is that it is metabolised to amphetamine derivatives, which contribute to a mild stimulant effect — useful for fatigue but a frequent cause of insomnia.<\/p>\n In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5–10 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful — tyramine restriction then becomes important.<\/p>\n The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Selgin?<\/h2>\n
How Does Selgin (selegiline) Work?<\/h2>\n
Comparing the MAO-B Inhibitors<\/h2>\n